Mycophenolate mofetil - Dermatology indications

You are here : Home > Formulary Search > Mycophenolate mofetil - Dermatology indications

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Amber

Formulations :

Capsules
Oral suspension
Tablets

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Associated Icons :

Off Label

SPC

Restrictions / Comments :

Important

Prescribe generically (except in transplant indications)

Documentation

Shared Care

Mycophenolate mofetil & mycophenolic acid - National Shared Care - update March 2025

Webpage

MHRA Drug Safety Update : Mycophenolate mofetil: pure red cell aplasia

Webpage

MHRA Drug Safety Update : Mycophenolate mofetil (CellCept) and mycophenolic acid: risk of hypogammaglobulinaemia and risk of bronchiectasis

PAD Profile

ChemicalSubstance :

Mycophenolate mofetil

Indication :

Dermatology indications

Group Name :

Keywords :

myositis, severe psoriasis, severe atopic dermatitis,/eczema, autoimmune bullous dermatoses, SLE, mycophenolic sodium, mycophenolic acid, RMOC, national shared care

Brand Names Include :

Arzip, CellCept, Myfortic, Myfenax, Ceptava

Important Information :

Latest Additions Date From :

Latest Additions Date To :

Guidelines :

Supporting Documents :

Other Indications

Below are listed other indications that Mycophenolate mofetil is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Dermatology indications.

Committee Recommendations (3)

02 Jul 25 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

Follow link to Shared Care Principles and Communication letters Shared Care principles and Communication letters

02 Aug 23 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee have agreed a local adaptation of the National Shared Care document, in reference to the routine monitoring of CRP (rather than ESR) in primary care for inflammatory indications

07 Dec 22 - Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

The Surrey Heartlands Integrated Care System Area Prescribing Committee (APC) has agreed the National Shared Care Protocol (with local adaptations) for mycophenolate mofetil and mycophenolic acid for patients within adult services (non-transplant indications)